	Area of Research	Phase I	Phase II	Phase III	Regulatory Filing & Approval[a]	Post Approval Research[b]
Multiple Myeloma (MM)						
REVLIMID® (lenalidomide)	Relapsed/refractory					
	Newly diagnosed					
	Maintenance					
POMALYST®/IMNOVID® (US/EU) (pomalidomide)	Relapsed/refractory[c]					
THALOMID®/Thalidomide Celgene® (US/EU) (thalidomide)	Newly diagnosed					
Anti-CD38 Antibody: MOR202[d]						
Myelodysplastic Syndromes (MDS)						
VIDAZA® (azacitidine for injection)						
REVLIMID® (lenalidomide)	Deletion 5q					
	Non-deletion 5q					
CC-486	Lower-risk					
sotatercept (ACE-011)[e]						
ACE-536[e]						
Acute Myeloid Leukemia (AML)						
VIDAZA® (azacitidine for injection)	AML (20%-30% blasts) (EU)					
	AML (>30% blasts) (EU)					
CC-486	Post-induction AML maintenance					
DOT 1L Inhibitor: EPZ-5676[f]						

[a]For information on approved uses, please refer to approved product labeling. [b]Includes Celgene-sponsored and Celgene-supported studies. [c]In the US, regulatory approval is based on pivotal phase II data; phase III program ongoing. [d]In collaboration with MorphoSys AG. [e]In collaboration with Acceleron Pharma. [f]In collaboration with Epizyme, Inc.

REVLIMID®, POMALYST®, IMNOVID®, THALOMID®, Thalidomide Celgene®, and VIDAZA® are registered trademarks of Celgene Corporation.

© 2014 Celgene Corporation 06/14

	Area of Research	Phase I	Phase II	Phase III	Regulatory Filing & Approval[a]	Post Approval Research[b]
Lymphoma						
REVLIMID® (lenalidomide)	Mantle cell lymphoma: Relapsed/refractory (US)					
	Mantle cell lymphoma: Relapsed/refractory (EU)					
	Diffuse large B-cell: Maintenance					
	Diffuse large B-cell (ABC-subtype): First-line					
	Indolent lymphoma: Relapsed/refractory					
	Follicular lymphoma: First-line					
	Adult T-cell leukemia-lymphoma (Japan)					
ISTODAX® (romidepsin) for injection	Cutaneous T-cell lymphoma (US)[c]					
	Peripheral T-cell lymphoma: Relapsed/refractory (US)[c]					
	Peripheral T-cell lymphoma: Relapsed/refractory (Japan)					
	Peripheral T-cell lymphoma: First-line					
Btk Inhibitor: CC-292						
PPM™ Pleiotropic Pathway Modulator: CC-122	Diffuse large B-cell					
Chronic Lymphocytic Leukemia (CLL)						
REVLIMID® (lenalidomide)	Maintenance: Second-line					
Btk Inhibitor: CC-292						
Anemias						
sotatercept (ACE-011)[d]	Renal anemia with metabolic bone disease					
	Diamond blackfan anemia					
	Beta-thalassemia					
	MDS					
ACE-536[d]	Beta-thalassemia					
	MDS					

[a]For information on approved uses, please refer to approved product labeling. [b]Includes Celgene-sponsored and Celgene-supported studies. [c]Filing for regulatory approval based on pivotal phase II data.
[d]In collaboration with Acceleron Pharma.

REVLIMID® and ISTODAX® are registered trademarks of Celgene Corporation. PPM™ is a trademark of Celgene Corporation.

© 2014 Celgene Corporation 06/14

	Area of Research	Phase I	Phase II	Phase III	Regulatory Filing & Approval[a]	Post Approval Research[b]
Solid Tumors						
ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) (US)/ (paclitaxel formulated as albumin-bound nanoparticles) (EU)	Breast: Metastatic					
	Breast: Metastatic (first-line, triple negative)					
	Non-small cell lung: Advanced (first-line) (US, Japan)					
	Pancreatic: Advanced (first-line)					
	Pancreatic: Adjuvant					
	Gastric: Metastatic (Japan)[c]					
Dual TORK Inhibitor: CC-223						
Dual TORK/DNA PK Inhibitor: CC-115						
PPM™ Pleiotropic Pathway Modulator: CC-122						
CC-486						
Inflammation & Immunology						
OTEZLA® (apremilast)	Psoriatic arthritis					
	Psoriasis					
	Ankylosing spondylitis					
	Behçet's disease					
	Rheumatoid arthritis					
	Atopic dermatitis					
	Crohn's disease					
	Ulcerative colitis					
GED-0301	Crohn's disease					
pomalidomide	Systemic sclerosis					
CC-220	Sarcoidosis					
	Systemic sclerosis					
	Cutaneous/Systemic lupus erythematosus					
CC-90001	Fibrosis					
Cellular Therapies						
BIOVANCE®[d,e] (human amniotic membrane allograft)	Wound management					
extracellular matrix[f]	Wound management					
PDA-001	Crohn's disease					
PDA-002	Peripheral artery disease/Diabetic foot ulcers					

[a]For information on approved uses, please refer to approved product labeling. [b]Includes Celgene-sponsored and Celgene-supported studies. [c]Trial conducted by licensee partner, Taiho Pharmaceuticals Co. Ltd.
[d]Regulated under Section 361 of the Public Health Service Act. [e]Processed for Alliqua Biomedical by Celgene Cellular Therapeutics. [f]510(k) device manufactured for Alliqua Biomedical by Celgene Cellular Therapeutics.

ABRAXANE®, OTEZLA®, and BIOVANCE® are registered trademarks of Celgene Corporation. PPM™ is a trademark of Celgene Corporation.

© 2014 Celgene Corporation 06/14